Medication info

Olmesartan Medoxomil and Amlodipine Besilate Tablet 10/40 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Amlodipine Besylate›13.888mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Dongsung Pharmaceutical Co., Ltd.
Appearance
Brownish-red, round film-coated tablet
Packaging
30 tablets (10 tablets/PTP X 3)
Approval status
Expired

MFDS item code 201904376 · Approved 2019.06.26

This product's status changed to Expired on 2024.06.26. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet once daily with water, with or without food. It is recommended that the tablet be taken at the same time each day, if possible (e.g., in the morning). It is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted before administering this drug; however, switching directly to this drug may be considered if blood pressure is not controlled with monotherapy using the individual components. The maximum dose of this drug is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Use of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced intravascular volume: In patients who may have reduced intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This drug should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this drug, under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
Child dose
Safety and efficacy have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Dongsung Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential Hypertension
View approved original text

Essential hypertension is important to control blood pressure, and this medication is used when blood pressure is not adequately controlled with either Amlodipine or Olmesartan Medoxomil alone. These drugs lower blood pressure, reduce the risk of cardiovascular complications, and help overall blood pressure management. They are effective in improving patients' blood pressure conditions to maintain health. Therefore, it is used for the treatment of essential hypertension.

How to take

Adult dose

Administer 1 tablet once daily with water, with or without food. It is recommended that the tablet be taken at the same time each day, if possible (e.g., in the morning). It is recommended that the doses of the individual components (amlodipine or olmesartan medoxomil) be adjusted before administering this drug; however, switching directly to this drug may be considered if blood pressure is not controlled with monotherapy using the individual components. The maximum dose of this drug is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Use of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced intravascular volume: In patients who may have reduced intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This drug should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this drug, under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.

Child dose

Safety and efficacy have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately once pregnancy is confirmed. Patients with allergies to components in this medication, those who are pregnant or breastfeeding, patients with severe liver disease, certain heart and biliary diseases, patients undergoing kidney dialysis, those in shock, and certain diabetic patients should not take this medication. Patients with fluid or salt depletion may experience excessively low blood pressure at the beginning of treatment, so their condition should be carefully monitored and appropriate treatment should be received if symptoms occur. Patients with certain heart diseases should be particularly cautious, as vasodilation may lead to sudden hypotension. Patients with weakened heart function or impaired kidney function may also experience worsening of kidney function while taking this medication, so regular check-ups are necessary. This medication may cause various side effects, including dizziness, headache, low blood pressure, edema, gastrointestinal disturbances, skin rashes, etc. If any abnormal symptoms appear, medical consultation should be sought immediately. This medication should not be used during pregnancy, and if a pregnancy is planned or confirmed, it should be replaced with a safer drug. If breastfeeding, the decision to use this medication should be made carefully. Children under 18 years of age are not recommended for use, as its safety and efficacy have not been established in this population. The elderly may have decreased kidney and liver function, so they should start with a low dose and be monitored carefully. In case of overdose, hypotension and cardiac arrhythmias may occur, so immediate medical attention is required.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • decreased sensation
  • syncope
Show 79 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • back pain
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • pit edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin
  • decreased hematocrit
  • cholelithiasis
  • female breast neoplasm
  • deterioration of cerebral infarction
  • gum bleeding
  • postural dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • chest burning
  • gastritis
  • shingles
  • diplopia
  • insomnia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • flushing
  • fatigue
  • edema
  • palpitations
  • dizziness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is recommended to maintain the storage temperature between 1 degree and 30 degrees Celsius at room temperature. Proper storage will help maintain the medication's efficacy and safety.

Appearance and packaging

Appearance

Brownish-red, round film-coated tablet

Package unit

30 tablets (10 tablets/PTP X 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.